Ionis Pharmaceuticals, Inc. Form 4 Filings

IONIS PHARMACEUTICALS INC (IONS) reported that executive vice president, chief legal officer and general counsel Patrick R. O'Neil acquired 63 shares of common stock on August 31, 2026 through the company’s employee stock purchase plan at $51.306 per share. Following this purchase, he directly holds 59,205 shares. According to the plan terms described, these 63 shares may not be sold until February 28, 2027, and the filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan.

IONIS PHARMACEUTICALS INC (IONS) reports that Chief Executive Officer and director Brett P. Monia acquired 98 shares of common stock on August 31, 2026 through the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share. After this transaction, Monia directly holds 242,760 shares of Ionis common stock. According to the plan terms, these 98 shares may not be sold until February 28, 2027. No Rule 10b5-1 trading plan is reported for this transaction.

IONIS PHARMACEUTICALS INC (IONS) reports that executive vice president Brian Birchler acquired 58 shares of common stock on August 31, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share.

The footnote states these shares may not be sold until February 28, 2027. Following this transaction, Birchler directly holds 102,883 shares of Ionis common stock.

IONIS PHARMACEUTICALS INC director Michael R. Hayden reported two open-market purchases of common stock by Genworks 2 Consulting, Inc., an entity through which his spouse holds shares with sole voting and investment power. Genworks 2 acquired 15,000 shares on July 30, 2026 at a weighted-average price of $53.38 and 5,000 shares on July 31, 2026 at a weighted-average price of $51.60, for a total of 20,000 additional indirectly held shares. Hayden also reports direct ownership of 54,298 Ionis common shares.

Reikes Peter N reported acquisition or exercise transactions in this Form 4 filing.

Ionis Pharmaceuticals Inc granted director Peter N Reikes 3,399 Restricted Stock Units on July 15, 2026 under its Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. The RSUs vest in three equal annual installments starting July 15, 2027 and will be fully vested on July 15, 2029. Following this award, Reikes holds 3,399 RSUs directly, all unvested as of the grant date.

HANTSON LUDWIG reported acquisition or exercise transactions in this Form 4 filing.

Ionis Pharmaceuticals director Ludwig Hantson received a grant of 3,399 Restricted Stock Units on July 15, 2026 under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Each RSU is a contingent right to one share of common stock or its cash value, vesting in three equal annual installments from July 15, 2027 and fully vesting on July 15, 2029. As of the grant date, 0 RSUs were vested and he holds 3,399 RSUs in total.

Ionis Pharmaceuticals director Joan E. Herman reported the vesting of 5,220 Restricted Stock Units on July 15, 2026, which were settled into 5,220 shares of common stock at $0.0000 per share. Following this derivative exercise, she directly holds 51,306 common shares and 2,301 Restricted Stock Units.

IONIS PHARMACEUTICALS director Spencer R. Berthelsen reported vesting of 5,220 Restricted Stock Units on July 15, 2026, converting into the same number of common shares at no cost. After this conversion, he directly holds 161,233 common shares and 2,301 RSUs. An additional 70 common shares are held indirectly by his daughter, for which he disclaims beneficial ownership.

Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett reported insider transactions involving company stock. On July 7, he executed open-market sales of 15,000 shares held indirectly through a trust at a weighted average price of $85.462 per share and 5,536 shares held directly at a weighted average price of $83.579 per share, under a pre-arranged Rule 10b5-1 trading plan. He also transferred 15,000 shares from direct to indirect ownership via a family trust and reported 15,000 restricted stock units that vested on January 15, 2026 and were paid in common shares. Following these transactions, he holds 75,018 shares directly, 15,000 shares indirectly through the trust, and 12,109 restricted stock units.

Ionis Pharmaceuticals director Allene M. Diaz exercised stock options and then sold the resulting shares. On July 7, 2026, Diaz exercised a non-qualified stock option to acquire 10,111 shares of common stock at $47.11 per share, then sold 10,111 shares in open-market transactions at a weighted average price of $85.4156 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Diaz directly owned 3,811 shares of Ionis common stock.

IONIS PHARMACEUTICALS INC EVP and Chief Development Officer Holly B. Kordasiewicz sold 362 shares of common stock in an open-market transaction at $84.30 per share on July 7, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, and she now holds 22,096 shares directly.

IONIS PHARMACEUTICALS INC director Michael J. Yang received equity awards as part of non-employee director compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units tied to common stock and 5,369 non-qualified stock options with an exercise price of $79.19 per share.

Both the RSUs and options vest 100% on the earlier of the first anniversary of grant or the next regularly scheduled annual stockholders’ meeting. The RSU delivery is deferred until the earlier of the fifth anniversary of vesting, a qualifying separation from service, or a change in control. After these grants, Yang directly holds 9,451 RSU-based common shares and 5,369 options. The company notes his 2026 annual equity compensation was adjusted to total no more than $400,000 in grant date fair value under its non-employee director policy.

IONIS PHARMACEUTICALS INC director Joseph Loscalzo received equity awards as part of non-employee director compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units, each representing one share of common stock or its cash equivalent, bringing his RSU-related holdings to 7,521 units.

He was also granted 5,369 Non-Qualified Stock Options with an exercise price of $79.19 per share. Both the RSUs and options vest 100% on the earlier of the first anniversary of grant or the next annual stockholders’ meeting, with RSUs delivered on the July 15 following vesting. The company’s Non-Employee Director Compensation Policy caps his 2026 annual equity compensation at $400,000 based on grant date fair value under FASB Topic ASC 718.

IONIS PHARMACEUTICALS INC director Joan E. Herman received new equity awards as part of non-employee director compensation. On July 1, 2026, Herman was granted 2,301 Restricted Stock Units, each representing a right to receive one share of Ionis common stock or its cash equivalent, subject to vesting.

On the same date, Herman was also granted options on 5,369 shares of common stock at an exercise price of $79.19 per share. Both the RSUs and options vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, consistent with the company’s non-employee director compensation policy that caps 2026 equity compensation at $400,000 based on grant-date fair value.

Ionis Pharmaceuticals director Joseph Klein III reported multiple equity transactions in company stock. On July 1, 2026, he exercised options covering 11,518 shares of common stock at an exercise price of $39.94 per share and sold 11,518 shares in open-market transactions at weighted average prices around $79 per share pursuant to a Rule 10b5-1 trading plan adopted on November 25, 2025. He also received grants of 2,301 restricted stock units and 5,369 non-qualified stock options with a strike price of $79.19 per share under the company’s non-employee director compensation programs. A separate filing entry notes 200 shares held indirectly by his son, which he disclaims as beneficially owned.

IONIS PHARMACEUTICALS INC director equity awards: Non-employee director Michael R. Hayden received a grant of 2,301 Restricted Stock Units and 5,369 non-qualified stock options on July 1, 2026 as compensation. After the RSU grant, he holds 12,198 common-share equivalents directly.

The options have a $79.19 exercise price and both awards vest 100% on the earlier of the first anniversary of grant or the next annual stockholder meeting. Under the company’s non-employee director compensation policy, the 2026 equity awards were adjusted so Hayden’s total annual equity compensation does not exceed $400,000 based on grant date fair value.

Ionis Pharmaceuticals director Allene M. Diaz received equity awards as part of non-employee director compensation. On July 1, 2026, Diaz was granted 2,301 Restricted Stock Units and a Non-Qualified Stock Option for 5,369 shares of common stock at an exercise price of $79.19 per share.

The RSUs and options were granted under the company’s Amended and Restated 2002 Non-Employee Directors' Stock Option Plan and were adjusted so total 2026 equity compensation does not exceed $400,000 in grant date fair value under FASB Topic ASC 718. Both awards vest 100% on the earlier of the first anniversary of grant or the next annual stockholder meeting.

IONIS PHARMACEUTICALS INC director Spencer R. Berthelsen received equity awards as non-cash compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units, each representing one share of Ionis common stock or its cash equivalent. These RSUs vest 100% on the earlier of the first anniversary of grant or the next regularly scheduled annual stockholder meeting, and will be delivered on the following July 15.

He was also granted 5,369 non-qualified stock options with an exercise price of $79.19 per share under the Amended and Restated 2002 Non-Employee Directors' Stock Option Plan, vesting 100% on the same schedule and not exercisable as of the grant date. Following the RSU grant, he holds 7,521 RSUs. The company states that, under its Non-Employee Director Compensation Policy, these grants were adjusted so that his 2026 annual equity compensation does not exceed $400,000 based on grant date fair value under FASB Topic ASC 718.

Ionis Pharmaceuticals EVP and Chief Business Officer Joseph Baroldi reported indirect spouse transactions in Ionis common stock. On June 26, 2026, Baroldi’s spouse exercised options for a total of 5,635 shares of common stock at exercise prices of $32.60 and $56.78 per share and then sold 5,635 shares in an open-market transaction at a weighted average price of $80.1595 per share under a pre-arranged Rule 10b5-1 Trading Plan. Following these transactions, Baroldi holds 48,522 shares directly, and his spouse holds 4,669 shares indirectly attributable to him.

IONIS PHARMACEUTICALS INC executive Patrick R. O’Neil sold 3,069 shares of common stock in an open-market transaction. The shares were sold at $80.00 per share, and he now directly holds 61,470 shares following the sale.

The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which typically means it was scheduled in advance rather than timed discretionarily.

Ionis Pharmaceuticals executive Eugene Schneider reported an exercise-and-sale transaction in company stock. On June 26, 2026, he exercised options to acquire 26,000 shares of common stock at $60.89 per share, then sold 26,000 shares in open-market trades at a weighted-average price of $81.046 per share.

The sales were executed under a pre-arranged Rule 10b5-1 Trading Plan adopted on November 19, 2025. After these transactions, Schneider directly held 77,114 shares of Ionis common stock.

Ionis Pharmaceuticals CEO Brett P. Monia reported a series of option exercises paired with open-market sales of common stock. Over June 24–26, 2026, he exercised options covering 85,637 shares and sold the same number of shares in the market, a net disposition.

Sales included 50,000 shares at a weighted average price of $80.59, 21,072 shares at $78.49, and 14,565 shares at $78.4128. The filing states these sales were made pursuant to a Rule 10b5-1 Trading Plan. After the transactions, he directly holds 245,571 shares of common stock and 99,872 non-qualified stock options.

Ionis Pharmaceuticals EVP Research Eric Swayze reported an open-market sale of company stock. On June 25, 2026, he sold 10,602 shares of Common Stock at a weighted average price of $79.1824 per share in a transaction coded as an open-market sale.

The sale was executed under a Rule 10b5-1 trading plan adopted on March 6, 2026, indicating it was pre-arranged rather than opportunistic. Following the sale, Swayze directly held 21,759 shares of Ionis Pharmaceuticals common stock, and an additional 318 shares were reported as indirectly owned through his son.

Ionis Pharmaceuticals EVP and Chief Development Officer Holly B. Kordasiewicz reported an exercise-and-sell transaction in Ionis common stock. On June 12, 2026, she sold a total of 60,846 shares in open-market sales, including 19,842 shares at a weighted average price of $74.0503 per share and 41,004 shares at a weighted average price of $73.0934 per share.

The sales were made under a pre-arranged Rule 10b5-1 Trading Plan adopted on March 13, 2026, meaning the trades were scheduled in advance. On the same date, she exercised non-qualified stock options covering a total of 60,846 shares of common stock at exercise prices of $32.60, $56.78, and $60.89 per share, converting derivative awards into shares that were then largely sold for liquidity.

IONIS PHARMACEUTICALS INC director Spencer R. Berthelsen exercised stock options and sold shares on the same day. He exercised non-qualified stock options covering 8,000 shares of Common Stock at an exercise price of $24.42 per share and then sold 8,000 shares in an open-market transaction at $73.49 per share pursuant to a Rule 10b5-1 Trading Plan adopted on September 12, 2025. After these transactions, he directly owned 156,013 shares of Common Stock. The filing also notes 70 shares of Common Stock held by his daughter, for which he disclaims beneficial ownership.

Ionis Pharmaceuticals director Peter N. Reikes received a grant of non-qualified stock options covering 10,753 shares of common stock. The options have an exercise price of $75.13 per share and were awarded under the company’s Amended & Restated 2002 Non-Employee Directors' Stock Option Plan.

The grant vests in three equal annual installments, with the first tranche vesting and becoming exercisable on June 4, 2027, and the options becoming fully vested and exercisable on June 4, 2029. The options expire on June 4, 2036. This is a compensation-related award rather than an open-market purchase or sale.

Ionis Pharmaceuticals director Ludwig Hantson received a grant of non-qualified stock options covering 10,753 shares of common stock at an exercise price of $75.13 per share. The options were granted at no cost as director compensation, vesting in three equal annual installments starting on June 4, 2027, and will be fully vested by June 4, 2029. The options expire on June 4, 2036, and were not exercisable as of the grant date.

IONIS PHARMACEUTICALS INC director Spencer R. Berthelsen reported an option exercise paired with a share sale. On June 1, 2026, he exercised a non-qualified stock option for 8,000 shares of common stock at $24.42 per share and then sold 8,000 shares in an open-market transaction at $75.67 per share. After these transactions, he directly held 156,013 shares of common stock. The filing also shows 70 shares held indirectly by his daughter, for which he disclaims beneficial ownership. The sale was executed under a Rule 10b5-1 Trading Plan adopted on September 12, 2025, indicating it was pre-arranged.

Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported an exercise-and-sell transaction in company stock. On May 13–14, Monia exercised options to acquire a total of 4,536 shares of common stock at an exercise price of $32.60 per share, then sold the same number of shares in open-market trades at weighted average prices of about $78.01 and $78.68. The sales were carried out under a pre-arranged Rule 10b5-1 Trading Plan adopted on December 8, 2025. Following these transactions, Monia directly holds 242,662 shares of Ionis common stock, indicating that only a small portion of the position was sold.

Ionis Pharmaceuticals director Joseph Loscalzo reported paired option exercises and stock sales on May 4, 2026. He sold a total of 77,289 shares of Common Stock in open-market transactions at weighted average prices of $75.58 and $74.90, under a pre-arranged Rule 10b5-1 Trading Plan adopted on November 18, 2025. To fund these sales, he exercised non-qualified stock options covering 77,289 shares at exercise prices between $38.06 and $64.80. Following the transactions, he continued to hold more than 36,000 shares of Ionis stock directly.

Ionis Pharmaceuticals director Joseph Klein III exercised a non-qualified stock option for 10,111 shares of common stock at an exercise price of $47.11 per share and, on the same date, sold 10,111 shares in open-market transactions under a pre-arranged Rule 10b5-1 Trading Plan. The sales consisted of 8,680 shares at a weighted-average price of $73.3530 and 1,431 shares at a weighted-average price of $74.4474. Following these transactions, Klein held 11,014 shares of Ionis common stock directly. An additional 100 shares are held indirectly by his son, and Klein disclaims beneficial ownership of those shares.

Ionis Pharmaceuticals executive Joseph Baroldi reported an open-market sale of company stock. On this Form 4, the EVP and Chief Business Officer sold 1,626 shares of Ionis Pharmaceuticals common stock on April 28, 2026 at a weighted average price of $71.7877 per share in an open-market transaction.

The sale was made pursuant to a Rule 10b5-1 Trading Plan adopted by Baroldi on November 25, 2025. After the transaction, he directly owned 44,909 shares of common stock. A separate holding entry shows 4,347 shares of common stock held indirectly by his spouse.

IONIS PHARMACEUTICALS INC director Lynne B. Parshall reported selling 5,000 shares of common stock in open-market transactions. The sales occurred on April 15, 2026 in two tranches: 4,466 shares at a weighted average price of $76.19 and 534 shares at a weighted average price of $76.97.

These trades were executed under a pre-arranged Rule 10b5-1 Trading Plan adopted on May 6, 2025, indicating they were scheduled in advance. Following the transactions, Parshall directly holds 51,344 shares of Ionis common stock.

Ionis Pharmaceuticals EVP Kyle Jenne reported routine equity compensation activity involving restricted stock units and common shares. On April 15, 2026, Jenne exercised 12,226 Restricted Stock Units, each representing a right to receive one share of Ionis common stock pursuant to a prior award.

In connection with this vesting, on April 16, 2026, Jenne completed an automatic sale of 4,902 common shares to cover required tax withholding obligations under the company’s equity incentive plan, at a weighted average price of $75.171 per share, with individual trades ranging from $75.06 to $75.26. Following these transactions, Jenne directly holds 23,713 shares of common stock and 74,402 Restricted Stock Units, which continue to vest in four equal annual installments.

Ionis Pharmaceuticals EVP Brian Birchler reported routine equity compensation activity and a related tax sale. He acquired 1,875 shares of common stock on conversion of Restricted Stock Units that vested under a prior award. The filing notes each RSU converts into one share of Ionis common stock.

To cover required tax withholding obligations from this vesting, 973 common shares were automatically sold at a weighted average price of $75.042 per share, with individual sale prices ranging from $75.01 to $75.06. After these transactions, Birchler directly holds 67,500 common shares, while 48,926 Restricted Stock Units remain outstanding and continue to vest in four equal annual installments.

IONIS PHARMACEUTICALS INC EVP and Chief Business Officer Joseph Baroldi reported RSU vesting and a related tax sale. On April 15, 2026, 10,837 Restricted Stock Units vested and were converted into 10,837 shares of common stock at a conversion price of $0.00 per share.

On April 16, 2026, 5,619 shares of common stock were sold at a weighted average price of $74.56 per share in an automatic sale to cover required tax withholding obligations under the company’s equity incentive plan. Following these transactions, Baroldi directly holds 46,535 common shares and has indirect ownership of 4,347 shares held by his spouse.

Ionis Pharmaceuticals director Joseph Klein III exercised stock options and sold shares on April 1, 2026. He exercised options for 12,000 shares at $38.06 and 10,321 shares at $41.08, acquiring a total of 22,321 common shares. He then sold 20,105 shares at a weighted average price of $75.503 and 2,216 shares at $75.954 in open-market transactions pursuant to a Rule 10b5-1 Trading Plan adopted on November 26, 2025. After these transactions, he held 11,014 shares directly. An additional 100 shares are held indirectly by his son, for which he disclaims beneficial ownership.

Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, sold 6,193 shares of Common Stock in an open-market transaction at a weighted average price of $74.0535 per share on April 2, 2026. The sale was made pursuant to a Rule 10b5-1 Trading Plan adopted on November 24, 2025. After this transaction, Devers directly holds 16,348 shares of Ionis Pharmaceuticals common stock.

Ionis Pharmaceuticals executive Eugene Schneider reported an open-market sale of 5,812 shares of Common Stock. The shares were sold at a weighted average price of $70.9715 per share on March 19, 2026, under a pre-arranged Rule 10b5-1 trading plan. After the transaction, Schneider directly holds 63,890 shares.

Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported a series of stock option exercises followed by open-market sales of common stock. On March 16, 2026, she exercised options to acquire a total of 174,999 shares of common stock at exercise prices of $32.6000, $37.5800, $56.7800 and $60.8900 per share. That same day, she sold 215,048 shares of common stock in open-market transactions at weighted average prices of $72.3810 and $72.7650 per share. On March 17, 2026, she sold an additional 10,172 shares at a weighted average price of $73.2070 per share, bringing total reported sales to 225,220 shares. The filing states these sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. Following the transactions, Hougen directly owns 82,660 shares of Ionis common stock.

Ionis Pharmaceuticals executive Patrick R. O'Neil reported an open-market sale of 10,148 shares of common stock at an average price of $75.2525 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.

Following this sale, O'Neil directly holds 62,211 Ionis shares. The reported sale price reflects a weighted average, with individual trades completed between $74.98 and $75.51 per share.

Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported a series of option exercises and stock sales. On March 9–10, 2026, Monia exercised non-qualified stock options covering 148,454 shares of common stock at an exercise price of $60.89 per share.

Across the same two days, Monia sold 160,773 shares of common stock in open-market transactions at weighted average prices in the mid‑$70 range. These sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Following the transactions, Monia directly owns 242,662 shares of Ionis Pharmaceuticals common stock.

Ionis Pharmaceuticals EVP Kyle Jenne exercised stock options and sold shares in a planned trade. He exercised options for 37,277 shares of Common Stock at exercise prices of $34.69 and $46.10 per share, then sold 37,277 shares in open-market transactions at weighted average prices of $75.502 and $76.30 per share.

The sales were made under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following these transactions, Jenne directly holds 16,389 shares of Ionis Pharmaceuticals Common Stock.

Ionis Pharmaceuticals director Joseph Loscalzo reported option exercises and related share sales in early March. He exercised non-qualified stock options to receive common shares at an exercise price of $38.06 per share, then sold 1,032 common shares at weighted average prices around $80–$81.

The sales, executed on March 3–4, 2026, were carried out under a pre-established Rule 10b5-1 trading plan. After these transactions, Loscalzo directly owned 36,330 common shares of Ionis Pharmaceuticals.

Ionis Pharmaceuticals director Joseph Klein III reported mixed stock transactions involving option exercises and share sales. On March 3, 2026, he exercised non-qualified stock options into 16,000 shares of common stock at exercise prices of $40.05 and $42.88 per share, then sold 21,332 shares in open-market transactions at weighted-average prices between $78.615 and $81.025, pursuant to a Rule 10b5-1 trading plan adopted on November 25, 2025. After these trades, he held 11,014 shares directly and 100 shares were reported as held indirectly by his son, for which he disclaimed beneficial ownership.

IONIS PHARMACEUTICALS INC director Allene M. Diaz reported option exercises and share sales. On March 3, 2026, she exercised non-qualified stock options covering 40,321 shares of common stock at exercise prices of $38.06, $40.05, and $41.08 per share.

On the same date, she sold a total of 54,878 shares of common stock in open-market transactions at weighted average prices ranging from about $78.57 to $81.01, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. Following these transactions, she directly held 3,811 shares of Ionis common stock.

Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, reported multiple transactions on common stock and non-qualified stock options of Ionis Pharmaceuticals Inc.

Devers exercised derivative securities and acquired common shares through option exercises, then sold 20,106 shares of common stock in open-market transactions at weighted average prices of $79.115, $79.999, and $80.837. According to the disclosure, these sales were made under a Rule 10b5-1 trading plan adopted on November 24, 2025, with individual sale prices ranging from $78.61 to $81.01. After these transactions, Devers directly owned 22,541 shares of Ionis common stock.

Ionis Pharmaceuticals executive Frank Bennett reported multiple stock transactions. On March 3, 2026, the EVP and Chief Scientific Officer exercised non-qualified stock options, receiving 16,463 common shares at an exercise price of $32.60 per share and 48,626 shares at $60.89 per share. He then sold 71,600, 12,687 and 802 common shares in open-market trades at weighted average prices of $79.099, $79.8778 and $80.762 per share, respectively, under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 80,554 Ionis common shares.

Ionis Pharmaceuticals EVP and Chief Business Officer Joseph Baroldi reported a mix of option exercises and share sales in Ionis stock. In early March 2026, he and his spouse exercised non-qualified stock options into common stock and then sold a net 6,659 shares, including 4,096 directly owned shares at $79.36 per share.

Additional indirect sales by his spouse involved smaller blocks such as 2,088 shares at $80.4079 and 36 shares at $81.01, alongside option-related acquisitions at exercise prices of $32.60 and $56.78. Footnotes state that these sales were made under Rule 10b5-1 trading plans adopted by Baroldi and his spouse.